Risobis 35 Tablet
By Risobis
Rx
4 Tablet in a Strip

Composition
Risedronate(35mg)

Manufacturer - Zuci Pharma
B519, Pushpak Corner,Opp. Navyug School, Naroda, Ahmedabad 382330

Expires on or after
November, 2027

liver
Risobis 35 Tablet is considered safe for use in individuals with liver disease. Current evidence indicates that adjusting the dosage of Risobis 35 Tablet may not be necessary for these patients. It is advisable to consult with your doctor regarding the use of this medication in case of any liver-related concerns.

kidney
Risobis 35 Tablet should be used carefully in patients with kidney disease. Consult your doctor for potential dose adjustment. Avoid in severe kidney disease. No dose change needed in mild to moderate cases.

alcohol
Caution is advised when consuming alcohol with Risobis 35 Tablet. It is important to consult your doctor.

driving
Risobis 35 Tablet typically does not impact driving ability.

pregnancy
Caution is advised when using Risobis 35 Tablet during pregnancy. Limited human studies show potential risks, and animal studies suggest harm to the developing baby. Consult your doctor to weigh the benefits and risks before using this medication.

breastfeeding
Risobis 35 Tablet is considered safe during breastfeeding based on limited human data showing no significant risk to the baby.
| Habit Forming | No |
| Chemical Class | Bisphosphonate Derivative |
| Therapeutic Class | PAIN ANALGESICS |
| Action Class | Bone resorption inhibitor -Bisphosphonates |
₹234.3
Inclusive of all taxes
